Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (The BoMeR trial): Impact on response and time to progression

Authors :: Alvin Milner
Joanne Dean
Hang Quach
M. C. Copeman
Henry Miles Prince
Simon J. Harrison
Source :: Journal of Clinical Oncology. 28:8151-8151
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: 8151 Background: In relapsed multiple myeloma (MM), bortezomib (Btz) is often combined with dexamethasone (Dex), as adding Dex to Btz later in patients only achieving SD or PD improved overall resp...

Subjects :: Oncology
endocrine system
Cancer Research
medicine.medical_specialty
Bortezomib
business.industry
Time to progression
medicine.disease
immune system diseases
hemic and lymphatic diseases
Internal medicine
polycyclic compounds
medicine
In patient
business
hormones, hormone substitutes, and hormone antagonists
Multiple myeloma
Dexamethasone
medicine.drug

Full Text Access

Tools